Complications of cardiac catheterization in the current era: a single-center experience.
Consecutive cardiac catheterization procedures done over a 2-yr period (April 1996 to March 1998) were prospectively analyzed to determine and characterize procedure-related complications (in-hospital and 1-mo follow-up), as they occur at present. During the study period, 11,821 procedures (7,953 diagnostic and 3,868 therapeutic) were performed. The majority of procedures (> 60%) were done in high-risk patients. Stents were implanted in 33% of patients, and adjunctive abciximab was used in 6.6% of therapeutic procedures. The overall complication rate was 8% (3.6% of diagnostic procedures and 15.1% of therapeutic procedures). The procedure-related mortality rates were 0.2%, 0.1%, and 0.5% for total, diagnostic, and therapeutic procedures, respectively. Cardiac complications were seen in 3.9% (1.5% of diagnostic and 9% of therapeutic procedures). Emergency cardiac surgery was required in 0.05% of the diagnostic procedure group and 0.3% of the therapeutic procedure group (total, 0.1%). Despite marked changes in patient population and practice, the complication rates of cardiac catheterization remain very low.
Chandrasekar
B
B
Cardiac Catheterization Laboratory, Department of Medecine, Montreal Heart Institute, Montreal, Québec, Canada.
Doucet
S
S
Bilodeau
L
L
Crepeau
J
J
deGuise
P
P
Gregoire
J
J
Gallo
R
R
Cote
G
G
Bonan
R
R
Joyal
M
M
Gosselin
G
G
Tanguay
J F
JF
Dyrda
I
I
Bois
M
M
Pasternac
A
A
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000706:statistics & numerical data; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D006328:Cardiac Catheterization / Q000009:adverse effects* / Q000706:statistics & numerical data; D003327:Coronary Disease / Q000453:epidemiology / Q000628:therapy*; D003430:Cross-Sectional Studies; D004868:Equipment Failure / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000009:adverse effects; D015994:Incidence; D007194:India; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D012306:Risk; D015607:Stents / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab